VEGFA and renal cell carcinoma: Because anti-VEGF treatment was found to have immunomodulatory effects on different types of immune cells, including myeloid cells and regulatory T cells (Treg) [93,94,95,96], clinical trials with the combination of ICIs and anti-VEGF agents were investigated in RCC.